<DOC>
	<DOC>NCT00338182</DOC>
	<brief_summary>The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.</brief_summary>
	<brief_title>AZD1152 in Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Histological or cytological confirmation of a solid, malignant tumour At least one measurable or nonmeasurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Participation in an investigational drug study within the 21 days prior to therapy or those who have not recovered from the effects of an investigational study drug Recent major surgery within 4 weeks prior to entry into the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>